HLB bioStep

At a glance

HLB bioStep filed 63 disclosures in the last 12 months, including 28 insider, 8 5% holder and 1 buyback. The most recent key filing was on Oct 13: A major holder's stake fell from 19.91% to 17.61% (off-market sale).

Revenue for 2025 was ₩74.1B, up 27.3% on 2024. It made an operating loss of ₩8.6B. Debt was 54% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩29.5B and operating loss of ₩4.5B.

The 2025 annual report lists 150 employees with an average tenure of 4.4 years and average pay of ₩61.7M, #885 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩219.1M each on average. It paid no cash dividend for 2025. 에이치엘비㈜ and related parties held 16.93% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 17.61% on Oct 13.

From the 2025 annual report

Staff: 150 (93 men, 57 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩9.3B. Directors and auditors: 7, paid ₩1.3B in total.

No cash dividend was paid for 2025.

Largest shareholder

에이치엘비㈜ holds 14.54%; with 4 related parties the group holds 16.93% of common shares at year end (from 16.68% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports